Aerojet Completes Testing of SM-3 Blk IB TDACS
Aerojet, a GenCorp (NYSE: GY) company, announced that it accomplished several key developmental milestones on its Standard Missile-3 (SM-3) Blk IB Throttleable Divert and Attitude Control System (TDACS) by completing a series of full-up system performance tests.
SM-3 is being developed as part of the Missile Defense Agency's sea-based Aegis Ballistic Missile Defense System. The missiles are being deployed on Aegis cruisers and destroyers to defend against short-to-intermediate range ballistic missile threats in the mid-course phase of flight. Raytheon is the prime contractor for the development of SM-3.
The successful ground static testing advances SM-3 Blk IB TDACS toward full qualification. It highlights Aerojet's leading role in providing reliable propulsion solutions for both the Missile Defense Agency and U.S. Navy missions. "These tests confirm the readiness of the TDACS for the upcoming critical flight test," said Aerojet's Vice President of Missile Defense, Michael Bright. "We look forward to a successful flight test."
Aerojet supports the next generation of sea- and land-based U.S. missile defense capabilities by providing reliable, low-risk propulsion technologies. In addition to developing the SM-3 Blk IB TDACS, Aerojet is currently producing MK 72 and MK 104 rocket motors, and is developing the SM-3 Blk IIA TDACS - the planned missile variant upgrade to the SM-3 Blk IB - as well as working the technologies needed for SM-3 Blk IIB.
Aerojet is a world-recognized aerospace and defense leader principally serving the missile and space propulsion, defense and armaments markets. GenCorp is a leading technology-based manufacturer of aerospace and defense products and systems with a real estate segment that includes activities related to the entitlement, sale, and leasing of the company's excess real estate assets. Additional information about Aerojet and GenCorp can be obtained by visiting the companies' websites at http://www.Aerojet.com and http://www.GenCorp.com.